文献速递造血干细胞移植与细胞治疗

CD34+ T细胞去除异基因造血细胞移植中抗胸腺细胞球蛋白的暴露

Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2022-01-01

该回顾性药代动力学/药效学分析纳入554例首次接受CD34+ T细胞去除异基因造血细胞移植的患者,用经验证的人群药代动力学模型估算移植后兔抗胸腺细胞球蛋白(rATG)暴露。移植后rATG暴露≥55 AU×天/毫升与更高的非复发死亡风险相关(风险比3.42,95%CI 1.26-9.30)。

要点

  • 移植后rATG低暴露(<30 AU×天/毫升)与非复发死亡风险降低及CD4+免疫重建概率升高相关。
  • 获得CD4+免疫重建的患者5年非复发死亡降低七倍(P<.0001)。
  • 移植后rATG暴露≥55 AU×天/毫升与非复发死亡(HR 3.42,95%CI 1.26-9.30)及急性移植物抗宿主病(HR 2.28,95%CI 1.01-5.16)风险升高相关。

核心结论

  • 移植后高rATG暴露与T细胞去除移植后CD4+免疫重建不良导致的非复发死亡升高相关。
  • 作者认为采用个体化药代动力学导向的rATG给药以达到最佳暴露可能改善移植后生存。

研究设计与样本

  • 回顾性药代动力学/药效学分析,纳入554例首次接受清髓性预处理后CD34+ T细胞去除异基因造血细胞移植的患者,年龄范围0.1-73岁。
  • 使用经验证的人群药代动力学模型估算移植后rATG暴露(曲线下面积,单位AU×天/毫升),采用Cox比例风险模型和多状态竞争风险模型分析。

主要发现

  • 移植后rATG暴露中位值为47 AU×天/毫升(范围0-101 AU×天/毫升)。
  • 移植后曲线下面积<30 AU×天/毫升与非复发死亡风险降低(P<.01)及获得CD4+免疫重建概率升高(P<.001)相关。
  • 获得CD4+免疫重建的患者5年非复发死亡降低七倍(P<.0001)。
  • 获得CD4+免疫重建的概率:<30 AU×天/毫升组较30-55 AU×天/毫升组高2.5倍,<30 AU×天/毫升组较≥55 AU×天/毫升组高3倍。
  • 多变量分析中,移植后rATG暴露≥55 AU×天/毫升与非复发死亡风险升高相关(风险比3.42;95%置信区间1.26-9.30);在恶性肿瘤亚组(n=515)中,≥55 AU×天/毫升组非复发死亡增加十倍,30-55 AU×天/毫升组增加七倍(均与<30 AU×天/毫升组比较);移植后rATG暴露≥55 AU×天/毫升与急性移植物抗宿主病风险升高相关(风险比2.28;95%置信区间1.01-5.16)。

临床怎么用

  • 作者认为采用个体化药代动力学导向的rATG给药以达到最佳暴露可能改善移植后生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditional weight-based dosing results in variable rabbit antithymocyte globulin (rATG) clearance that can delay CD4+ T-cell immune reconstitution (CD4+ IR) leading to higher mortality. In a retrospective pharmacokinetic/pharmacodynamic (PK/PD) analysis of patients undergoing their first CD34+ T-cell-depleted (TCD) allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning with rATG, we estimated post-HCT rATG exposure as area under the curve (arbitrary unit per day/milliliter [AU × day/mL]) using a validated population PK model. We related rATG exposure to nonrelapse mortality (NRM), CD4+ IR (CD4+ ≥50 cells per µL at 2 consecutive measures within 100 days after HCT), overall survival, relapse, and acute graft-versus-host disease (aGVHD) to define an optimal rATG exposure. We used Cox proportional hazard models and multistate competing risk models for analysis. In all, 554 patients were included (age range, 0.1-73 years). Median post-HCT rATG exposure was 47 AU × day/mL (range, 0-101 AU × day/mL). Low post-HCT area under the curve (<30 AU × day/mL) was associated with lower risk of NRM (P < .01) and higher probability of achieving CD4+ IR (P < .001). Patients who attained CD4+ IR had a sevenfold lower 5-year NRM (P < .0001). The probability of achieving CD4+ IR was 2.5-fold higher in the <30 AU × day/mL group compared with 30-55 AU × day/mL and threefold higher in the <30 AU × day/mL group compared with the ≥55 AU × day/mL group. In multivariable analyses, post-HCT rATG exposure ≥55 AU × day/mL was associated with an increased risk of NRM (hazard ratio, 3.42; 95% confidence interval, 1.26-9.30). In the malignancy subgroup (n = 515), a tenfold increased NRM was observed in the ≥55 AU × day/mL group, and a sevenfold increased NRM was observed in the 30-55 AU × day/mL group compared with the <30 AU × day/mL group. Post-HCT rATG exposure ≥55 AU × day/mL was associated with higher risk of a GVHD (hazard ratio, 2.28; 95% confidence interval, 1.01-5.16). High post-HCT rATG exposure is associated with higher NRM secondary to poor CD4+ IR after TCD HCT. Using personalized PK-directed rATG dosing to achieve optimal exposure may improve survival after HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lakkaraja M, Scordo M, Mauguen A, et al. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. Blood Adv. 2022. PMID: 34788361. doi:10.1182/bloodadvances.2021005584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。